Many patients with atrial fibrillation (AF) received triple antithrombotic therapy after undergoing a percutaneous coronary intervention (PCI) and receiving cardiac stent. Triple therapy consists of warfarin plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and low-dose aspirin. But is triple therapy the best approach? This practice, while widely employed, is not entirely evidence-based. It’s actually the result of combining two evidence-based strategies – one to... Read More
Could automated, web-based cognitive behavioral therapy (CBT) replace flesh-and-blood healthcare practitioners? Can computers deliver healthcare at lower cost and similar quality to face-to-face interactions with humans? Several web-based CBT programs have been developed and are now being marketed directly to consumers. But do they actually work?
According to results of the America Insomnia Survey, up to 50% of adults in the U.S. experience difficulty sleeping. Of those... Read More
My response to the question will be NO - Liraglutide based on the Leader trial cannot be added in the algorithm of DM-2 treatment as a second line agent next to Metformin. The logic is as follows:
Goal of DM-2 treatment is to lower the A1C value and BG level by adding another agent to the first line. Already the pt is at 8.1 or more. The LEADER trial discussed does not provide the outcome on these two parameters (not even the script providing the trail information), though the... Read More